Liposomal amphotericin-B (AmBisome) is now becoming first choice for the treatment of visceral leishmaniasis (kala-azar) patients due to high efficacy and less toxicity. The reported incidence of hypersensitivity reactions to liposomal amphotericin-B (AmBisome), especially during therapy, is very rare. We report two patients with kala-azar: one developed breathing difficulties and hypotension followed by shock and the other had facial angioedema with chest tightness during treatment. Both patients were managed with immediate action of injection: adrenaline, diphenhydramine and hydrocortisone. In our experience, AmBisome can cause severe hypersensitivity reactions that warrant proper support and close supervision.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232346PMC
http://dx.doi.org/10.1177/0049475514543655DOI Listing

Publication Analysis

Top Keywords

liposomal amphotericin-b
12
amphotericin-b ambisome
12
hypersensitivity reactions
8
hypersensitivity reaction
4
reaction liposomal
4
ambisome
4
ambisome infusion
4
infusion liposomal
4
ambisome choice
4
choice treatment
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!